Targeting conformational changes in C-reactive protein to inhibit pro-inflammatory actions

Area of Science:

• Biochemistry
• Immunology
• Translational Medicine

Background:

• C-reactive protein (CRP) is a key marker of acute inflammation.
• CRP exists in distinct forms with opposing functions, potentially exacerbating tissue damage.
• Targeting harmful CRP actions is crucial for developing new therapies.

Purpose of the Study:

• To develop a novel therapeutic agent targeting deleterious CRP functions.
• To investigate the agent's ability to inhibit pro-inflammatory actions without affecting host defense.
• To evaluate the therapeutic potential in models of transplant rejection and kidney injury.

Main Methods:

• Development of a low molecular weight phosphocholine-mimetic.
• Assessment of the agent's binding to pentameric CRP (pCRP).
• Evaluation of the agent's effects on CRP conformation and inflammatory signaling.
• Testing in preclinical models of allograft transplant rejection and renal ischemia-reperfusion injury.

Main Results:

• The novel agent effectively binds to pCRP.
• Inhibition of conformation change-mediated pro-inflammatory CRP actions was demonstrated.
• Therapeutic benefits were observed in preventing allograft transplant rejection.
• The agent showed efficacy in mitigating renal ischemia-reperfusion injury.

Conclusions:

• A novel phosphocholine-mimetic effectively targets and modulates CRP activity.
• This therapeutic strategy reduces inflammation and tissue damage while preserving host defense.
• The findings support the development of CRP-targeted therapies for inflammatory diseases and organ injury.